Medrysone

DB00253

small molecule approved

Deskripsi

Medrysone is a corticosteroid used in ophthalmology.

Struktur Molekul 2D

Berat 344.4877
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed following oral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

168 Data
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Medrysone.
Tacrolimus Tacrolimus may increase the immunosuppressive activities of Medrysone.
Phenylephrine The risk or severity of hypertension can be increased when Medrysone is combined with Phenylephrine.
Aminoglutethimide The therapeutic efficacy of Medrysone can be decreased when used in combination with Aminoglutethimide.
Insulin human The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin human.
Insulin lispro The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin lispro.
Insulin glargine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin glargine.
Insulin pork The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin pork.
Troglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Troglitazone.
Glimepiride The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glimepiride.
Sulfisoxazole The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sulfisoxazole.
Disopyramide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Disopyramide.
Acarbose The risk or severity of hyperglycemia can be increased when Medrysone is combined with Acarbose.
Metformin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metformin.
Sulfadiazine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Rosiglitazone.
Acetohexamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Acetohexamide.
Quinine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Quinine.
Miglitol The risk or severity of hyperglycemia can be increased when Medrysone is combined with Miglitol.
Chlorpropamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Chlorpropamide.
Nateglinide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Nateglinide.
Pentamidine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Pentamidine.
Mifepristone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Mifepristone.
Tolazamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Tolazamide.
Repaglinide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Repaglinide.
Phenformin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Phenformin.
Sulfamethoxazole The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sulfamethoxazole.
Glyburide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glyburide.
Glipizide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glipizide.
Gliclazide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Gliclazide.
Tolbutamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Tolbutamide.
Pioglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Pioglitazone.
Bromocriptine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Bromocriptine.
Gliquidone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Gliquidone.
Mitiglinide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Mitiglinide.
Sitagliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sitagliptin.
Sunitinib The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sunitinib.
Exenatide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Exenatide.
Mecasermin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Mecasermin.
Pramlintide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Pramlintide.
Glisoxepide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glisoxepide.
Insulin aspart The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin aspart.
Insulin detemir The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin detemir.
Insulin glulisine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin glulisine.
Glymidine The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glymidine.
AICA ribonucleotide The risk or severity of hyperglycemia can be increased when Medrysone is combined with AICA ribonucleotide.
Buformin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Buformin.
Vildagliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Vildagliptin.
Voglibose The risk or severity of hyperglycemia can be increased when Medrysone is combined with Voglibose.
NN344 The risk or severity of hyperglycemia can be increased when Medrysone is combined with NN344.
AMG-222 The risk or severity of hyperglycemia can be increased when Medrysone is combined with AMG-222.
Bisegliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Bisegliptin.
Alogliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Alogliptin.
Dapagliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dapagliflozin.
Saxagliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Saxagliptin.
Liraglutide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Liraglutide.
Gosogliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Gosogliptin.
Linagliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Linagliptin.
Canagliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.
Glibornuride The risk or severity of hyperglycemia can be increased when Medrysone is combined with Glibornuride.
Benfluorex The risk or severity of hyperglycemia can be increased when Medrysone is combined with Benfluorex.
Empagliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.
Albiglutide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Albiglutide.
Dulaglutide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dulaglutide.
Lobeglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Lobeglitazone.
Netoglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Netoglitazone.
Rivoglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Rivoglitazone.
Ciglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Ciglitazone.
Lixisenatide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Lixisenatide.
Insulin beef The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin beef.
Insulin degludec The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin degludec.
Insulin peglispro The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Ipragliflozin.
Dutogliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dutogliptin.
Allicin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Allicin.
Tofogliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hyperglycemia can be increased when Medrysone is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Teneligliptin.
Omarigliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Omarigliptin.
Carmegliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Carmegliptin.
Gemigliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Gemigliptin.
Anagliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Anagliptin.
Evogliptin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Evogliptin.
Sotagliflozin The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sotagliflozin.
Balaglitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hyperglycemia can be increased when Medrysone is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Carbutamide.
Guar gum The risk or severity of hyperglycemia can be increased when Medrysone is combined with Guar gum.
Metahexamide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metahexamide.
Semaglutide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Semaglutide.
Taspoglutide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Taspoglutide.
Englitazone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Englitazone.
Tirzepatide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hyperglycemia can be increased when Medrysone is combined with Gastric inhibitory polypeptide.
Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Medrysone.
Cyclosporine The risk or severity of adverse effects can be increased when Medrysone is combined with Cyclosporine.
Digoxin The risk or severity of adverse effects can be increased when Medrysone is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Medrysone is combined with Acetyldigitoxin.

Target Protein

Steroid hormone receptor ERR1 ESRRA
Steroid hormone receptor ERR2 ESRRB
Estrogen-related receptor gamma ESRRG
Glucocorticoid receptor NR3C1

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Hms
    Suspension • 10 mg/1mL • Ophthalmic • US • Approved
  • Hms
    Solution / drops • 1 % • Ophthalmic • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul